CRISPR Patent Ruling Lifts Editas, Disappoints Intellia and CRISPR Therapeutics
US Decision Goes Against Nobel Prize Winners
A US decision to grant a CRISPR Cas9 patent to The Broad Institute lifts Editas but adds uncertainty to the IP estate of Intellia and CRISPR Therapeutics.
You may also be interested in...
New data show that a high dose of Intellia’s in vivo CRISPR-Cas9 based therapy is safe and effective for up to six months, which could unlock a new era in genetic disease treatment.
While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.